Sagimet Biosciences INC. (SGMT) — 8-K Filings

All 8-K filings from Sagimet Biosciences INC.. Browse 28 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (28)

Sagimet Biosciences Files 8-K on Officer Changes — Apr 21, 2026 Risk: medium
Sagimet Biosciences Inc. filed an 8-K on April 21, 2026, reporting on the departure of certain officers and compensatory arrangements. The filing also includes
Sagimet Biosciences Files 8-K Report — Dec 18, 2025 Risk: low
On December 18, 2025, Sagimet Biosciences Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, Other Events, and Financial Statements and
8-K Filing — Dec 17, 2025
Sagimet Biosciences Files 8-K — Oct 23, 2025 Risk: low
Sagimet Biosciences Inc. filed an 8-K on October 23, 2025, reporting on financial statements and exhibits. The company, formerly known as 3-V Biosciences, Inc.,
Sagimet Biosciences Changes Independent Auditor — Aug 22, 2025 Risk: low
Sagimet Biosciences Inc. announced on August 18, 2025, a change in its certifying accountant. The company has appointed PricewaterhouseCoopers LLP as its new in
Sagimet Biosciences Terminates Material Agreement — Aug 14, 2025 Risk: medium
On August 14, 2025, Sagimet Biosciences Inc. filed an 8-K report detailing the termination of a material definitive agreement. The filing also includes informat
Sagimet Biosciences Files 8-K on Financials — Aug 13, 2025 Risk: low
Sagimet Biosciences Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD
Sagimet Biosciences Reports Board Changes and Officer Appointments — Jun 10, 2025 Risk: medium
On June 6, 2025, Sagimet Biosciences Inc. filed an 8-K report detailing changes in its board of directors and the election of new officers. The filing also addr
Sagimet Biosciences Files 8-K — Jun 4, 2025 Risk: low
On June 4, 2025, Sagimet Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No
Sagimet Biosciences Files 8-K Report — May 8, 2025 Risk: low
On May 8, 2025, Sagimet Biosciences Inc. filed an 8-K report detailing results of operations, other events, and financial statements. The company, formerly know
Sagimet Biosciences Announces Board and Executive Changes — Apr 30, 2025 Risk: medium
Sagimet Biosciences Inc. announced on April 29, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company elect
Sagimet Biosciences Files 8-K Report — Mar 12, 2025 Risk: low
On March 12, 2025, Sagimet Biosciences Inc. filed an 8-K report detailing results of operations and financial condition, along with other events and financial s
Sagimet Biosciences Files 8-K — Mar 11, 2025 Risk: low
Sagimet Biosciences Inc. filed an 8-K on March 11, 2025, reporting other events and financial statements. The company, formerly known as 3-V Biosciences, Inc.,
Sagimet Biosciences Inc. Files Current Report — Feb 14, 2025 Risk: low
Sagimet Biosciences Inc. reported on February 14, 2025, that its Series A Common Stock trades under the symbol SGMT on The Nasdaq Global Market. The company, in
Sagimet Biosciences Files 8-K Report — Jan 2, 2025 Risk: low
On January 2, 2025, Sagimet Biosciences Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
Sagimet Biosciences Inc. Files 8-K on Financials — Nov 14, 2024 Risk: low
Sagimet Biosciences Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statem
Sagimet Biosciences Enters Material Definitive Agreement — Aug 16, 2024 Risk: medium
On August 15, 2024, Sagimet Biosciences Inc. entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related to
Gilead Acquires Sagimet Biosciences for $275M — Aug 14, 2024 Risk: medium
Sagimet Biosciences Inc. announced on August 14, 2024, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for $275 million
Sagimet Biosciences Appoints New Directors, Adjusts Executive Pay — Aug 1, 2024 Risk: medium
Sagimet Biosciences Inc. announced on July 30, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company electe
Sagimet Biosciences Files 8-K Report — Jul 2, 2024 Risk: low
On July 2, 2024, Sagimet Biosciences Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no other specific events de
Sagimet Biosciences Holds 2024 Annual Meeting, Elects Directors — Jun 6, 2024 Risk: low
On June 5, 2024, Sagimet Biosciences Inc. filed an 8-K report detailing the results of its 2024 Annual Meeting of Stockholders held on June 4, 2024. The company
Sagimet Biosciences Files 8-K Report — May 23, 2024 Risk: low
On May 23, 2024, Sagimet Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The
Sagimet Biosciences Files 8-K on Operations and Financials — May 15, 2024 Risk: low
Sagimet Biosciences Inc. filed an 8-K on May 15, 2024, to report on its results of operations and financial condition, as well as to file financial statements a
Sagimet Biosciences Appoints New Directors, Adjusts Executive Pay — May 6, 2024 Risk: low
Sagimet Biosciences Inc. announced on May 3, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new direc
Sagimet Biosciences Appoints New CMO and CSO — Mar 25, 2024 Risk: medium
On March 20, 2024, Sagimet Biosciences Inc. announced the appointment of Dr. Michael R. McDevitt as Chief Medical Officer and Dr. Jeffrey W. Allen as Chief Scie
Sagimet Biosciences 8-K: Executive Compensation Arrangements Updated — Feb 2, 2024
Sagimet Biosciences Inc. filed an 8-K on February 2, 2024, reporting an event that occurred on January 31, 2024, related to changes in its executive compensatio
Sagimet Biosciences Files 8-K, Confirms Nasdaq Listing — Jan 30, 2024
Sagimet Biosciences Inc. filed an 8-K on January 30, 2024, reporting an event that occurred on January 25, 2024. This filing primarily serves to update administ
Sagimet Biosciences Files 8-K for Compliance, Nasdaq Listing Confirmed — Jan 22, 2024
Sagimet Biosciences Inc. filed an 8-K on January 22, 2024, primarily to satisfy filing obligations related to written communications under Rule 425 of the Secur

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX